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AbsTrACT
Objective The high degree of clinical overlap between 
atypical parkinsonian syndromes (aps) and parkinson’s 
disease (pD) makes diagnosis challenging. We aimed to 
identify novel diagnostic protein biomarkers of aps using 
multiplex proximity extension assay (pea) testing.
Methods cerebrospinal fluid (csF) samples from two 
independent cohorts, each consisting of aps and pD 
cases, and controls, were analysed for neurofilament 
light chain (NF-L) and Olink Neurology and Inflammation 
pea biomarker panels. Whole-cohort comparisons of 
biomarker concentrations were made between aps 
(n=114), pD (n=37) and control (n=34) groups using 
logistic regression analyses that included gender, age 
and disease duration as covariates.
results aps versus controls analyses revealed 11 
csF markers with significantly different levels in cases 
and controls (p<0.002). Four of these markers also 
reached significance (p<0.05) in aps versus pD analyses. 
Disease-specific analyses revealed lower group levels of 
FGF-5, FGF-19 and spOcK1 in multiple system atrophy 
compared with progressive supranuclear palsy and 
corticobasal syndrome. Receiver operating characteristic 
curve analyses suggested that the diagnostic accuracy 
of NF-L was superior to the significant pea biomarkers 
in distinguishing aps, pD and controls. The biological 
processes regulated by the significant proteins include 
cell differentiation and immune cell migration. Delta 
and notch-like epidermal growth factor-related receptor 
(DNeR) had the strongest effect size in aps versus 
controls and aps versus pD analyses. DNeR is highly 
expressed in substantia nigra and is an activator of the 
NOTch1 pathway which has been implicated in the 
aetiology of other neurodegenerative disorders including 
alzheimer’s disease.
Conclusions pea testing has identified potential novel 
diagnostic biomarkers of aps.
InTrOduCTIOn
The atypical parkinsonian syndromes (APS) include 
progressive supranuclear palsy (PSP), corticobasal 
syndrome (CBS) and multiple system atrophy 
(MSA). The high degree of clinical overlap between 
APS and Parkinson’s disease (PD) makes diagnosis 
challenging, and pathological diagnosis remains the 
gold standard.1 However, as we enter a new era of 
potential disease-modifying therapies,2 early and 
accurate diagnosis has never been more important.
Neurofilament light chain (NF-L), a marker of 
axonal degeneration of large-calibre myelinated 
axons, is a reliable differentiator of APS, PD and 
controls in cerebrospinal fluid (CSF)3 4 and plasma.5 
However, the level of NF-L does not differentiate 
between PSP, CBS and MSA,3 and it is also raised in 
other neurodegenerative disorders such as fronto-
temporal dementia (FTD).6
Proximity extension assay (PEA) technology 
is a 96-plex immunoassay for high-throughput 
fluid protein biomarker detection, using unique 
antibody–oligonucleotide protein binding for 
quantitative real-time polymerase chain reac-
tion (PCR)-based measurement.7 PEA biomarker 
measurement has previously been explored in 
neurological conditions such as traumatic brain 
injury.8 In addition, PEA appears to be less affected 
by the technical issues of multiplex enzyme-linked 
immunosorbent assay (ELISA) such as antibody 
cross-reactivity and inter-assay variability.9
We have used PEA biomarker measurement to 
identify diagnostic markers of APS that offer novel 
biological insights into these disorders. In partic-
ular, our study explores the role of inflammation 
which has been identified as a key component in the 
pathogenesis of Alzheimer’s disease (AD) and FTD 
via microglial activation pathways in biomarker10 
and genetic11 studies.
MeThOds
standard protocol approvals, registrations and 
patient consents
Two prospective cohorts, each consisting of subjects 
with PSP, CBS, MSA and PD, and controls, were 
recruited and followed up longitudinally. Cohort 
1 was recruited at The National Hospital for 
Neurology and Neurosurgery, London, between 
2012 and 2015 (Research Ethics Committee refer-
ence—12/LO/0640) for a Queen Square biomarker 
study of patients with APS.3 Cohort 2 was recruited 
between 2015 and 2017 as part of their involve-
ment in the PROSPECT-UK study (Research Ethics 
Committee reference—14/LO/1575), a longitu-
dinal observational study of patients with APS in 
the UK. Cohort 2 PD subject samples and clinical 
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data were obtained from PD patients in the placebo arm of the 
Exenatide trial (trial approval by Brent NHS Research Ethics 
Committee, London).12 Patient consent for the trial covered the 
use of samples and clinical data in related studies such as this 
one. CSF sampling, quality control and storage protocols imple-
mented in the trial were identical to the protocol outlined below.
Patients were assigned diagnoses according to current clinical 
diagnostic criteria. Of note, our application of the Movement 
Disorder Society (MDS) PSP diagnostic criteria13 identified 
probable PSP cases with clinical syndromes other than classical 
Richardson syndrome (RS), such as PSP-parkinsonism (PSP-P) 
and pure akinesia with gait freezing (PAGF). Baseline PSP 
rating scale (PSPRS) scores were obtained from patients with 
PSP and CBS on the same day of, but prior to, lumbar punc-
ture (LP) testing. For each patient, the following clinical data 
were recorded: gender, age at motor symptom onset, date of 
motor symptom onset, age at the point of LP, disease duration 
at the point of LP, alive/deceased status of subjects at the point 
of censoring (7 December 2018) and the total disease duration 
in deceased subjects (defined as date of motor symptom onset 
to the date of death). In addition, a thorough review of current 
clinical notes for all patients was carried out to ensure that their 
clinical diagnosis had not changed. A subset of deceased patients 
underwent postmortem examination at the Queen Square Brain 
Bank, London, for neuropathological confirmation of diagnosis.
LP/blood testing, sample handling and initial biomarker 
testing
Cases and controls underwent baseline LP testing. Cases and 
controls from cohort 1 also underwent venepuncture for blood 
testing at the same time as LP. CSF and blood samples were frozen 
and stored at −80ᵒC within 1 hour of sampling. Biomarker 
testing was performed on 0.5 mL aliquots and no aliquots had 
undergone interim freeze–thaw cycles. Blood-contaminated CSF 
samples (>500 red blood cells/μL) were excluded. Prior to PEA 
testing, CSF levels of the following markers were obtained using 
a separate aliquot of CSF: total-tau/phosphorylated-tau/Aβ1–42 
(INNOTEST ELISA—Fujirebio Europe N.V., Gent, Belgium) 
and NF-L (Simoa platform; Quanterix, Lexington, Massachu-
setts, USA). Samples from cohorts 1 and 2 were analysed on 
separate runs for the above biomarkers.
PeA testing
Biomarker panel testing was performed using multiplex PEA 
technology as previously described by Olink (Uppsala, Sweden).7 
Samples were simultaneously run on two panels, (1) Neurology 
and (2) Inflammation, each consisting of 92 biomarkers, with 
96 samples tested simultaneously on each run. Olink panel 
validation data are freely available online (https://www. olink. 
com/ data- you- can- trust/ validation/). The biological function of 
PEA markers of interest was obtained from the UniProt data-
base ( www. uniprot. org). Tissue expression of PEA markers of 
interest was assessed using publicly available data on the GTEx 
database ( www. gtexportal. org). The GTEx database consists 
of 8555 samples from 53 tissues (including 13 brain regions) 
of 544 donors for which RNAseq was conducted. The GTEx 
Project was supported by the Common Fund of the Office of 
the Director of the National Institutes of Health, and by NCI, 
NHGRI, NHLBI, NIDA, NIMH and NINDS. The data used for 
the analyses described in this manuscript were obtained from the 
GTEx Portal on 31 July 2018.
Samples from cohorts 1 (CSF and plasma) and 2 (CSF 
alone) were analysed on separate runs. The resulting data for 
each biomarker were given as a normalised protein expression 
(NPX) value. NPX is an arbitrary unit on a Log2 scale with data 
being normalised to minimise both intra-assay and inter-assay 
variation. We subsequently performed intensity normalisation 
(detailed description at www. olink. com/ content/ uploads/ 2018/ 
05/ Data- normalization- and- standardization_ v1. 0. pdf) of CSF 
NPX values across cohorts 1 and 2 to allow the combination of 
data sets to carry out whole-cohort analyses.
statistical analyses
All of the following statistical analyses were performed using 
Stata V.14.0. Figures were generated using Stata V.14.0 and R 
V.3.3.2. Group comparisons of baseline clinical data (continuous 
variables) were carried out using t-tests, with statistical signif-
icance defined as p value <0.05. All protein biomarkers that 
had a >5% subject failure rate and all subjects that had a >5% 
marker failure rate were excluded from analyses.
Group comparisons of intensity-normalised PEA marker 
data were carried out using two separate approaches. First, we 
combined subjects with PSP and CBS to form a ‘tau’ group, and 
subjects with MSA and PD combined to form a ‘synuclein’ group 
in order to carry out whole-cohort tau versus synuclein group 
comparisons with gender, age at the point of testing and disease 
duration at the point of testing as covariates. Second, subjects 
with PSP, CBS and MSA were combined to form one ‘APS’ group 
in order to carry out whole-cohort APS versus controls and APS 
versus PD group comparisons. Initially, whole-cohort APS versus 
controls analyses for all PEA markers and NF-L were carried 
out using logistic regression analyses, with gender and age at the 
point of testing as covariates. We then carried out whole-cohort 
APS versus PD group analyses for NF-L and all PEA markers 
that had reached significance in the whole-cohort APS versus 
controls analyses. For APS versus PD comparisons, we used 
logistic regression analyses, with gender, age at the point of 
testing and disease duration at the point of testing as covariates. 
The threshold for significant group differences in both analyses 
was set using the Benjamini-Hochberg correction method for 
multiple testing14 with a false discovery rate of 5%. We calcu-
lated disease-specific association statistics for all PEA markers 
that reached significance in whole-cohort APS versus controls 
and APS versus PD analyses.
We carried out separate receiver operating characteristic 
(ROC) curve analyses for whole-cohort APS versus controls 
and APS versus PD group comparisons. In each analysis, ROC 
curves were generated for the following variables: (1) covariates; 
(2) CSF NF-L; (3) combined significant CSF PEA markers; (4) 
covariates+CSF NF-L+combined significant CSF PEA markers.
In subjects with APS, the relationship between the levels of 
significant PEA markers and (1) NF-L levels (log-transformed) 
and (2) PSPRS scores was assessed using linear regression anal-
yses, with gender, age at the point of testing and disease duration 
at the point of testing as covariates.
resuLTs
A total of 151 cases and 34 controls were recruited to the study 
across two independent cohorts (table 1). All subjects under-
went baseline CSF sampling for NF-L and PEA marker testing. 
All subjects from cohort 1 underwent paired blood sampling 
for plasma PEA marker testing. Of note, we excluded eight 
patients with CBS who fulfilled criteria for a CSF profile that 
was indicative of underlying AD pathology—defined as a CSF 
tau:Aβ1–42>1.15 In addition, all PSP cases from cohort 1 
fulfilled probable RS criteria while the breakdown of cohort 2 
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Table 1 Summary of baseline clinical characteristics, CSF NF-L and clinical progression data
Cohort 1 Cohort 2
PsP
(n=33)
Cbs
(n=11)
MsA
(n=29)
Pd
(n=25)
COn
(n=30)
PsP
(n=21)
Cbs
(n=11)
MsA
(n=9)
Pd
(n=12)
COn
(n=4)
Gender male/female (%) 48/52 57/43 55/45 64/36 50/50 81/19 18/82 89/11 67/33 25/75
Age at motor symptom onset (years)—mean, SD 65.1*
6.2
64.5*
8.0
60.2*
5.9
55.8‡
8.1
  63.6*
6.2
59.4*
7.8
61.0*
9.2
50.7‡
6.0
  
Age at LP (years)—mean, SD 69.6†
5.9
68.4†
8.4
64.4†
5.8
67.4†‡
9.1
59.8*
9.9
67.2*
5.7
64.1*
7.5
65.6*
8.7
59.9†‡
6.1
65.0*
2.9
Disease duration at LP (years)—mean, SD 4.5*
2.5
3.9*
1.2
4.2*
2.2
11.6
6.1
  3.6*
2.0
4.7*
1.9
4.6*
2.6
9.2
3.1
  
PSPRS score—mean, SD 42.0‡
11.5
38.9
15.2
      30.6‡
9.1
30.4
10.8
      
CSF NF-L concentration (ng/L)—mean, SD 2225.2
*†‡§
913.4
2268.6
*†
1291.4
2991.0
*†‡
1462.2
963.0
†
565.8
630.6
*
278.9
3228.5
*†‡
1611.3
2547.3
*†§
1255.7
4671.6
*†‡
2768.9
980.3
218.7
868.5
236.4
% of subjects deceased at point of censoring 88 64 86 48   24 0 0 0   
Total disease duration in deceased group
(years)—mean, SD
7.2*
2.5
7.0*
2.5
7.1*
2.4
13.7
6.8
  6.0
2.3
NA NA NA   
No of pathologically confirmed cases 9
PSP=9
2
CBD=2
6
MSA=5
PSP=1
0   2
PSP=2
NA NA NA   
Only statistically significant (p<0.05) differences between continuous variables are noted from t-tests.
*vs PD in same cohort.
†vs controls in same cohort.
‡vs same measure in other cohort.
§vs MSA in same cohort.
CBS, corticobasal syndrome; CON, controls; CSF, cerebrospinal fluid; LP, lumbar puncture; MSA, multiple system atrophy; NA, data not available; NF-L, neurofilament light chain; 
PD, Parkinson’s disease; PSP, progressive supranuclear palsy; PSPRS, PSP rating scale.
Figure 1 Volcano plot of cerebrospinal fluid proximity extension assay 
biomarkers, highlighting significant markers that differentiated the atypical 
parkinsonian syndromes (aps) group from controls. Markers to the right of 
0 on the x-axis were higher in the aps group and markers to the left of 0 
on the x-axis were higher in controls. The threshold for p value significance 
(<0.002) was set using the Benjamini-hochberg correction method for 
multiple testing with a false discovery rate of 5%.
PSP cases fulfilling probable criteria were as follows: 15 RS; 4 
PSP-P; 2 PAGF.
CSF samples from all subjects underwent PEA marker testing 
for 184 markers (92 from the Neurology panel and 92 from 
the Inflammation panel). In total, 119/184 biomarkers (65 from 
the Neurology panel and 54 from the Inflammation panel) were 
detectable in the CSF of >95% of all subjects in both cohorts 
and were therefore used for further analyses. All subjects had a 
detectable result for >95% of the remaining 119 biomarkers. 
We carried out intensity normalisation across both cohorts to 
enable the combination of data sets to conduct whole-cohort 
analyses.
Our initial analyses did not reveal any markers that reached 
statistical significance in differentiating between tau and synu-
clein groups. We then combined PSP, CBS and MSA groups into 
one APS group. The ability of each biomarker to differentiate 
between the APS group and controls was assessed by carrying 
out individual logistic regression analyses that used gender and 
age at the point of testing as covariates. The resulting coeffi-
cient values, used as markers of group fold change, and p values 
were used to construct a volcano plot to highlight significant 
markers (figure 1). We identified 11 markers that reached statis-
tical significance.
We took forward the 11 significant markers from the 
whole-cohort APS versus controls analyses and assessed their 
ability to differentiate the APS group from the PD group by 
carrying out logistic regression analyses that used gender, age at 
the point of testing and disease duration at the point of testing 
as covariates (figure 2). We identified four markers with reduced 
CSF concentrations in APS cases as compared with PD cases, 
which were also reduced in APS versus controls. Although the 
remaining seven markers followed the same trends as in the APS 
versus controls analyses, these group differences did not reach 
statistical significance.
We did not detect any statistically significant (p<0.05) APS 
versus controls or APS versus PD differences using cohort 1 
plasma data when carrying out logistic regression analyses using 
the same covariates as in the CSF analyses above.
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Figure 2 Volcano plot of cerebrospinal fluid proximity extension assay 
biomarkers, highlighting significant markers that differentiated the atypical 
parkinsonian syndromes (aps) group from the parkinson’s disease (pD) 
group. Markers to the right of 0 on the x-axis were higher in the aps group 
and markers to the left of 0 on the x-axis were higher in the pD group. The 
threshold for p value significance (<0.05) was set using the Benjamini-
hochberg correction method for multiple testing with a false discovery rate 
of 5%.
Table 2 Disease-specific summary statistics of significant PEA CSF 
biomarkers
CsF 
biomarker
PsP (n=54) 
mean 
(nPX)
sd
Cbs 
(n=22) 
mean 
(nPX)
sd
MsA (n=38) 
mean (nPX)
sd
Pd (n=37) 
mean 
(nPX)
sd
COn (n=34) 
mean (nPX)
sd
FGF-5 3.26*†
0.54
3.28*†
0.52
2.93*†§¶
0.58
3.60†
0.53
3.52†§¶
0.46
MSR1 2.11*
0.40
2.08*†
0.39
2.02*
0.48
1.95*
0.50
1.58†‡§¶
0.48
VWC2 4.78*
0.49
4.93
0.55
4.55*‡
0.54
5.13†
0.51
5.06†§
0.51
VEGF-A 9.24*
0.46
9.34
0.54
8.98*‡
0.53
9.61†
0.46
9.48†§
0.55
ADAM22 7.64*‡
0.29
7.67
0.24
7.56*‡
0.26
7.84†§
0.25
7.78†§
0.26
DNER 10.02*
0.15
10.00*
0.17
9.96*‡
0.16
10.11†
0.14
10.08†§¶
0.13
UNC5C 2.14*
0.51
2.26
0.51
2.09*†
0.51
2.43†
0.43
2.46†§
0.47
ADAM23 3.00*
0.30
3.04
0.34
2.89*‡
0.33
3.21†
0.26
3.17†§
0.28
SPOCK1 7.15*†‡
0.29
7.12†
0.37
6.94*‡§¶
0.32
7.36†§
0.29
7.23†§
0.29
N2DL-2 4.13*
0.72
3.92*‡
0.71
3.90*‡
0.85
4.60†¶
0.74
4.52†§¶
0.86
FGF-19 4.53*†
0.55
4.70†
0.53
4.23*‡§¶
0.59
4.90†
0.51
4.79†§
0.54
Only statistically significant (p<0.05) differences are noted from logistic regression 
analyses.
*vs controls.
†vs MSA.
‡vs PD.
§vs PSP.
¶vs CBS.
CBS, corticobasal syndrome; CON, controls; CSF, cerebrospinal fluid; MSA, multiple 
system atrophy; NPX, normalised protein expression value; PD, Parkinson’s disease; 
PEA, proximity extension assay; PSP, progressive supranuclear palsy.
We assessed for disease-specific differences between PSP, CBS, 
MSA, PD and control groups in the significant PEA markers 
by carrying out whole-cohort logistic regression analyses using 
gender, age at testing and disease duration at testing as covari-
ates. Although we found significantly different levels of our 
identified markers between controls and each of the PSP, CBS 
and MSA groups, we found that the APS versus PD signals for 
FGF-5, FGF-19 and DNER were primarily being driven by 
lower levels in the MSA group. In addition, we found signifi-
cantly lower group levels of FGF-5, FGF-19 and SPOCK1 in 
MSA compared with PSP and CBS (table 2).
The biological function and tissue expression of the significant 
PEA markers are summarised below (table 3).
We carried out separate whole-cohort APS versus controls 
and APS versus PD ROC curve analyses to assess the diagnostic 
strength of the significant PEA markers in comparison with 
NF-L (figure 3).
Using whole-cohort APS group data, we did not detect any 
statistically significant relationships between the CSF levels of 
the significant PEA markers and both log-transformed CSF NF-L 
levels and PSP rating scale scores by conducting linear regres-
sion analyses using gender, age at testing and disease duration at 
testing as covariates.
dIsCussIOn
Our study highlights the application of high-throughput multiplex 
PEA testing to reveal novel biological insights into atypical parkin-
sonian disorders. The statistical methods used in the APS versus 
controls and APS versus PD analyses provides robust evidence for 
the diagnostic markers that we have identified.
The baseline clinical characteristics, CSF NF-L data and patho-
logical diagnosis data suggest a high level of diagnostic accuracy in 
our two cohorts which enabled a combined whole-cohort study. 
Our thorough current clinical notes review for each case ensured 
that patients had not subsequently developed clinical features 
suggestive of alternative diagnoses. In particular, none of the 
cohort 1 PD group cases had evidence of oculomotor dysfunction 
suggesting inadvertent inclusion of PSP-P cases. The mean disease 
duration at the point of diagnosis in this group was 11.6 years, and 
at this stage we would certainly expect to see oculomotor dysfunc-
tion in patients with PSP-P.16 Similarly, patients with PSP-P included 
in the cohort 2 PSP group fulfilled ‘probable’ MDS PSP diagnostic 
criteria.13 This means that all cases would have had the presence of 
slowed vertical saccades and/or a vertical supranuclear gaze palsy, 
both of which are highly suggestive of underlying PSP pathology, 
such that we do not believe this group inadvertently contained PD 
cases.
In addition, we intensity-normalised our PEA biomarker data 
across both cohorts to reduce inter-run variability, allowing us to 
combine data sets for better powered whole-cohort analyses.
Although our initial approach of creating tau and synuclein 
groups led to more pathologically homogeneous group compari-
sons, this did not yield any significant results. However, our subse-
quent whole-cohort analyses identified 11 CSF biomarkers that 
differentiated APS from controls. Four of these markers (FGF-5, 
FGF-19, DNER and N2DL-2) also differentiated APS from PD, 
with levels of the remaining seven markers not reaching statistical 
significance but following the same trend as in the APS versus 
controls analyses. Despite having heterogeneous pathology within 
the combined APS group, it is possible that the markers reaching 
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Table 3 Biological function (UniProt database) and tissue expression (GTEx database) of significant PEA CSF biomarkers
CsF biomarker Olink panel
Associated gene
(chromosomal location) biological function
Tissue with highest 
expression (median 
TPM)
brain region with 
highest expression 
(median TPM)
FGF-5
(fibroblast growth factor 5)
Inflammation FGF5
(4q21.21)
Regulation of cell proliferation and cell 
differentiation
Fibroblasts (18.9) Cerebellum (6.0)
MSR1
(macrophage scavenger 
receptor 1)
Neurology MSR1
(8p22.1)
A membrane glycoprotein implicated 
in the pathological deposition of 
cholesterol in arterial walls during 
atherogenesis
Lung (33.2) Hypothalamus (1.0)
VWC2
(von Willebrand factor C 
domain-containing protein 2)
Neurology VWC2
(7p12.2)
Bone morphogenetic protein 
antagonist which may play a role in 
neural development
Cerebellum (24.4) Cerebellum (24.4)
VEGF-A
(vascular endothelial growth 
factor A)
Inflammation VEGFA
(6p21.1)
Growth factor active in angiogenesis, 
vasculogenesis and endothelial cell 
growth
Thyroid (613.1) Cerebellum (39.7)
ADAM22
(disintegrin and 
metalloproteinase domain-
containing protein 22)
Neurology ADAM22
(7p21.12)
Regulation of cell adhesion and 
inhibition of cell proliferation
Cerebellum (87.4) Cerebellum (87.4)
DNER
(delta and notch-like 
epidermal growth factor-
related receptor)
Inflammation DNER
(2q36.3)
Activator of the NOTCH1 pathway. May 
mediate neuron–glia interaction during 
astrocytogenesis
Substantia nigra 
(124.9)
Substantia nigra (124.9)
UNC5C
(netrin receptor)
Neurology UNC5C
(4q22.3)
Mediates axon repulsion of neuronal 
growth cones in the developing 
nervous system
Thyroid (11.7) Cervical cord (8.2)
ADAM23
(disintegrin and 
metalloproteinase domain-
containing protein 23)
Neurology ADAM23
(2q33.3)
May play a role in cell–cell and cell–
matrix interactions
Frontal cortex (45.5) Frontal cortex (45.5)
SPOCK1
(testican 1)
Neurology SPOCK1
(5q31.2)
May play a role in cell–cell and cell–
matrix interactions
Cerebellum (314.3) Cerebellum (314.3)
N2DL-2
(UL16-binding protein 2)
Neurology ULBP2
(6q25.1)
Binds and activates the KLRK1/NKG2D 
receptor, mediating natural killer 
cytotoxicity
Fibroblasts (9.6) Cerebellum (5.0)
FGF-19
(fibroblast growth factor 19)
Inflammation FGF19
(11q13.3)
Involved in the suppression of bile acid 
biosynthesis through downregulation 
of CYP7A1 expression
Testis (0.5) Cerebellum (0.4)
CSF, cerebrospinal fluid; PEA, proximity extension assay; TPM, transcripts per kilobase million.
Figure 3 Receiver operating characteristic (ROc) curve analyses of: (a) atypical parkinsonian syndromes (aps) vs controls; (B) aps vs parkinson’s disease 
(pD). combined plot=significant Olink proximity extension assay markers+neurofilament light chain (NF-L)+covariates. covariates in aps vs controls 
analysis=age at testing and gender. covariates in aps vs pD analysis=age at testing, disease duration at testing and gender.
significance in the above analyses are, like NF-L, non-specific 
markers of more rapid rates of neurodegeneration seen in PSP, 
CBS and MSA in comparison with PD. However, it is more likely 
that we were underpowered to detect pathology-specific differ-
ences in biomarker concentrations when carrying out tau (PSP and 
CBS) versus synuclein (MSA and PD) analyses. This is suggested by 
the fact that we found significantly lower group levels of FGF-5, 
FGF-19 and SPOCK1 in MSA compared with PSP and CBS groups. 
It remains premature to suggest that these are disease-specific 
markers until further replication data in larger cohorts is obtained.
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Movement disorders
All but one of the significant PEA markers had lower levels in 
the APS group compared with both PD and controls. Although this 
trend draws parallels with the observation of lower CSF levels of 
Aβ1–42 in patients with AD compared with controls, thought to 
reflect the incorporation of Aβ1–42 into amyloid plaques,17 it is 
unclear as to why this is the case in our identified markers.
The biological processes regulated by the significant PEA 
markers include cell proliferation/differentiation, cell apoptosis, 
immune cell migration and neural development. Of particular 
interest, DNER had the strongest effect size (coefficient) of all of 
the markers in both APS versus controls and APS versus PD anal-
yses. DNER is highly expressed in substantia nigra, is an activator 
of the NOTCH1 pathway which has a role in neuronal and glial 
cell differentiation, and has previously been implicated in the aeti-
ology of AD.18
APS versus controls and APS versus PD ROC curve analyses 
revealed that the individual area under the curve values for CSF 
NF-L alone were superior to the combination of the significant 
PEA markers.
There is strong evidence that levels of NF-L can track and 
predict the rate of disease progression in PSP.19 The lack of a linear 
relationship between the levels of the significant PEA markers and 
both the level of NF-L and PSPRS scores suggest that these markers 
are unlikely to have prognostic value. However, this needs to be 
explored further with longitudinal biomarker measurements to 
assess the temporal pattern of these markers in relation to changing 
clinical rating scale scores.
In summary, we present promising findings using PEA biomarker 
technology to discover novel diagnostic markers of APS. Although 
outside of the scope of this study, follow-up work includes replica-
tion of our findings in larger cohorts of subjects with APS which, 
in turn, may lead to the discovery of disease-specific and pathol-
ogy-specific markers. A similar approach using phenotype group 
comparisons such as RS versus PSP-P/PAGF would also be of 
interest. In addition, we would aim to validate PEA as a reliable 
multiplex technique by comparing the levels of markers measured 
by PEA, single-molecule array and ELISA.
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